Canadian Thoracic Society Asthma Management Continuum–2010 Consensus Summary for children six years of age and over, and adults
MD Lougheed, C Lemière, SD Dell… - Canadian respiratory …, 2010 - Wiley Online Library
BACKGROUND/OBJECTIVE: To integrate new evidence into the Canadian Asthma
Management Continuum diagram, encompassing both pediatric and adult asthma …
Management Continuum diagram, encompassing both pediatric and adult asthma …
Addition of long‐acting beta2‐agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children
FM Ducharme, MN Chroinin… - Cochrane Database …, 2010 - cochranelibrary.com
Background Long‐acting inhaled ß 2‐adrenergic agonists (LABAs) are recommended as'
add‐on'medication to inhaled corticosteroids (ICS) in the maintenance therapy of asthmatic …
add‐on'medication to inhaled corticosteroids (ICS) in the maintenance therapy of asthmatic …
Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial
CA Sorkness, RF Lemanske Jr, DT Mauger… - Journal of Allergy and …, 2007 - Elsevier
BACKGROUND: More evidence is needed on which to base recommendations for treatment
of mild-moderate persistent asthma in school-aged children. OBJECTIVE: The Pediatric …
of mild-moderate persistent asthma in school-aged children. OBJECTIVE: The Pediatric …
Effect of ADRB2 polymorphisms on response to longacting β2-agonist therapy: a pharmacogenetic analysis of two randomised studies
ER Bleecker, DS Postma, RM Lawrance, DA Meyers… - The Lancet, 2007 - thelancet.com
Background New evidence has suggested that people with asthma who are homozygous for
arginine at aminoacid 16 of the β 2-adrenergic receptor (ADRB2) might not benefit from …
arginine at aminoacid 16 of the β 2-adrenergic receptor (ADRB2) might not benefit from …
[图书][B] Pharmacology and physiology for anesthesia e-book: foundations and clinical application
HC Hemmings, TD Egan - 2012 - books.google.com
Better understand the complexities of pharmacology and physiology relevant to your
practice with the brand-new medical reference book, Pharmacology and Physiology for …
practice with the brand-new medical reference book, Pharmacology and Physiology for …
Network perturbation analysis in human bronchial epithelial cells following SARS-CoV2 infection
G Nunnari, C Sanfilippo, P Castrogiovanni… - Experimental cell …, 2020 - Elsevier
Background SARS-CoV2, the agent responsible for the current pandemic, is also causing
respiratory distress syndrome (RDS), hyperinflammation and high mortality. It is critical to …
respiratory distress syndrome (RDS), hyperinflammation and high mortality. It is critical to …
Scientific rationale for using a single inhaler for asthma control
PJ Barnes - European Respiratory Journal, 2007 - Eur Respiratory Soc
Clinical trials have recently demonstrated that using a budesonide/formoterol combination
inhaler as regular maintenance treatment twice daily but also as a rescue therapy for …
inhaler as regular maintenance treatment twice daily but also as a rescue therapy for …
In silico identification of a β2-adrenoceptor allosteric site that selectively augments canonical β2AR-Gs signaling and function
SD Shah, C Lind, F De Pascali… - Proceedings of the …, 2022 - National Acad Sciences
Activation of β2-adrenoceptors (β2ARs) causes airway smooth muscle (ASM) relaxation and
bronchodilation, and β2AR agonists (β-agonists) are front-line treatments for asthma and …
bronchodilation, and β2AR agonists (β-agonists) are front-line treatments for asthma and …
Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review
S Joos, A Miksch, J Szecsenyi, B Wieseler, U Grouven… - Thorax, 2008 - thorax.bmj.com
Objective: To systematically review the evidence for the medium to long term benefits and
risks of montelukast as add-on therapy to inhaled corticosteroids (ICS) in comparison with …
risks of montelukast as add-on therapy to inhaled corticosteroids (ICS) in comparison with …
Cardioselective beta‐blockers for reversible airway disease
SR Salpeter, TM Ormiston, EE Salpeter… - Cochrane Database …, 1996 - cochranelibrary.com
Background Beta‐blocker therapy has mortality benefit in patients with hypertension, heart
failure and coronary artery disease, as well as during the perioperative period. These drugs …
failure and coronary artery disease, as well as during the perioperative period. These drugs …